Splenic marginal zone lymphoma natural history, complications and prognosis
|
Splenic marginal zone lymphoma Microchapters |
|
Differentiating Splenic marginal zone lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Splenic marginal zone lymphoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Splenic marginal zone lymphoma natural history, complications and prognosis |
|
FDA on Splenic marginal zone lymphoma natural history, complications and prognosis |
|
CDC on Splenic marginal zone lymphoma natural history, complications and prognosis |
|
Splenic marginal zone lymphoma natural history, complications and prognosis in the news |
|
Blogs on Splenic marginal zone lymphoma natural history, complications and prognosis |
|
Directions to Hospitals Treating Splenic marginal zone lymphoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Hemoglobin level of less than 12 g/dL, lactate dehydrogenase level higher than normal, blood serum albumin levels of less than 3.5 g/dL, and some genetic mutations, such as mutations in NOTCH2 are associated with a particularly poor prognosis among patients with splenic marginal zone lymphoma.
Prognosis
- Poor prognosis criteria [1]
- Hemoglobin level of less than 12 g/dL
- Lactate dehydrogenase level higher than normal
- Blood serum albumin levels of less than 3.5 g/dL
- Some genetic mutations, such as mutations in NOTCH2, are also correlated with shorter survival
References
- ↑ Arcaini, L. (2006). "Splenic marginal zone lymphoma: a prognostic model for clinical use". Blood. 107 (12): 4643–4649. doi:10.1182/blood-2005-11-4659. ISSN 0006-4971.